Patients with cardioembolic ischemic stroke are commonly prescribed direct oral anticoagulants (DOACs), such as dabigatran (a direct thrombin inhibitor) and factor Xa inhibitors (e.g., apixaban and rivaroxaban), or warfarin to reduce the risk of recurrent stroke. A major concern in anticoagulant therapy is the risk of intracerebral hemorrhage, which is associated with a high mortality rate. Cerebral microbleeds (MBs), small asymptomatic brain hemorrhages detectable by susceptibility-weighted imaging (SWI) on magnetic resonance imaging (MRI), are associated with increased hemorrhagic stroke risk. This study evaluated the incidence of new MBs during 1 year of anticoagulation therapy in patients after cardioembolic stroke. Patients indicated for anticoagulant therapy after cardioembolic stroke and monitored in the cerebrovascular outpatient clinic of our department underwent brain MRI at baseline and after 1 year of therapy. The occurrence of new MBs was assessed using SWI sequences. MBs were categorized based on location into 3 groups: deep (dMBs), lobar (lMBs), and infratentorial (iMBs). A total of 79 patients were included, 53 of whom were male (67.1%), with a median age of 71 years (IQR: 64-76). The majority of patients (n = 50, 63.3%) were treated with apixaban, 16 patients (20.3%) with dabigatran, and 13 patients (16.5%) with warfarin. Baseline MRI revealed MBs in 17 patients (21.5%), including dMBs in 2, lMBs in 16, and iMBs in 2 patients. Follow-up MRI showed new MBs in 8 patients (10.1%), with new dMBs in 1, lMBs in 5, and iMBs in 4 patients. No statistically significant differences were observed in MBs the incidence of new MBs between anticoagulant groups (P = .912). Over 1 year of anticoagulant therapy, new MBs were detected in 10.1% of patients, predominantly in lobar and infratentorial regions. No differences in the incidence of new MBs were identified between the different anticoagulant groups.

• MeSH
• Anticoagulants * adverse effects   therapeutic use   MeSH
• Cerebral Hemorrhage * chemically induced   diagnostic imaging   epidemiology   MeSH
• Stroke * prevention & control   MeSH
• Dabigatran adverse effects   therapeutic use   MeSH
• Incidence MeSH
• Middle Aged MeSH
• Humans MeSH
• Magnetic Resonance Imaging methods   MeSH
• Pyrazoles adverse effects   therapeutic use   MeSH
• Pyridones adverse effects   therapeutic use   MeSH
• Secondary Prevention * methods   MeSH
• Aged MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Observational Study MeSH

Hemofilie A je vrozené krvácivé onemocnění, které bývá často komplikované krvácením do kloubů a rozvojem různě závažných kloubních změn. V případě hypetrofické synovitidy je důraz kladen na konzervativní možnosti jejího vstřebání. K tomu je zapotřebí dlouhodobě navýšit minimální hladinu koagulačního faktoru VIII (FVIII) tak, aby se zabránilo i možným mikrokrvácením, které k rozvoji synovitidy zásadně přispívají. Nový rekombinantní koaguiační faktor VIII, efanesoctocog α, umožňuje zcela revolučním způsobem navýšit hladinu tak, že šance na vstřebání synovitidy bez invazivního výkonu jsou velmi vysoké.

Haemophilia A is a congenital bleeding disorder that is often complicated by bleeding into the joints and the development of joint changes. In the case of hypetrophic synovitis, the focus is on conservative treatment options for its resolution. This approach requires to increase concentration of coagulation factor VIII (FVIII) trough levels for longer period of time in order to prevent every possible microbleeds, which contribute significantly to the development of synovitis. The new recombinant factor VIII, efanesoctocog α, allows levels to be raised in a completely revolutionary way, so during such a treatment the chances of full resolution of synovitis without invasive approaches are very high.

• MeSH
• Hemarthrosis * etiology   drug therapy   MeSH
• Hemophilia A * drug therapy   complications   MeSH
• Coagulants pharmacology   therapeutic use   MeSH
• Humans MeSH
• Adolescent MeSH
• Check Tag
• Humans MeSH
• Adolescent MeSH
• Male MeSH
• Publication type
• Case Reports MeSH

IMPORTANCE: Baseline cerebral microbleeds (CMBs) and APOE ε4 allele copy number are important risk factors for amyloid-related imaging abnormalities in patients with Alzheimer disease (AD) receiving therapies to lower amyloid-β plaque levels. OBJECTIVE: To provide prevalence estimates of any, no more than 4, or fewer than 2 CMBs in association with amyloid status, APOE ε4 copy number, and age. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data included in the Amyloid Biomarker Study data pooling initiative (January 1, 2012, to the present [data collection is ongoing]). Data from 15 research and memory clinic studies were pooled and harmonized. Participants included individuals for whom data on age, cognitive status, amyloid status, and presence of CMBs were available. Data were analyzed from October 22, 2023, to April 26, 2024. MAIN OUTCOMES AND MEASURES: The main outcomes were age, cognitive status, amyloid status and presence, location, and number of CMBs. Presence of amyloid pathology was determined based on 42 amino acid-long form of amyloid-β peptide (Aβ42) levels in cerebrospinal fluid or on amyloid-positron emission tomography. Presence and, in a subset, location (lobar vs deep) and number of CMBs were determined on magnetic resonance imaging (locally with visual rating). RESULTS: Among 4080 participants included in the analysis, the mean (SD) age was 66.5 (8.9) years, and 2241 (54.9%) were female. A total of 2973 participants had no cognitive impairment (cognitive unimpairment [CU]), and 1107 had mild cognitive impairment (MCI) or AD dementia (ADD). One thousand five hundred and thirteen participants (37.1%) had amyloid pathology, 1368 of 3599 (38.0%) with data available were APOE ε4 carriers, and 648 (15.9%) had CMBs. In the CU group, amyloid pathology and APOE ε4 copy number were not associated with presence of any, no more than 4, or fewer than 2 CMBs but were associated with increased odds of lobar CMBs (odds ratio [OR] for amyloid, 1.42 [95% CI, 1.20-1.69], P < .001; OR for 2 vs 0 alleles, 1.81 [95% CI, 1.19-2.74], P = .006; OR for 1 vs 0 alleles, 1.10 [95% CI, 0.83-1.46], P = .49; and OR for 2 vs 1 allele, 1.64 [95% CI, 0.90-2.97], P = .11; overall P = .02). In the MCI-ADD group, amyloid pathology was associated with presence of any CMBs (OR, 1.51 [95% CI, 1.17-1.96], P = .002), no more than 4 CMBs (OR, 1.44 [95% CI, 1.18-1.82], P = .002), and fewer than 2 CMBs (OR 1.34 [95% CI, 1.03-1.74], P = .03) but not lobar CMBs. APOE ε4 copy number was associated with presence of any (OR for 2 vs 0 alleles, 1.72 [95% CI, 0.88-3.35], P = .11; OR for 1 vs 0 alleles, 0.78 [95% CI, 0.59-1.04], P = .09; and OR for 2 vs 1 allele, 2.20 [95% CI, 1.32-3.67], P = .002; overall P < .001) and no more than 4 CMBs (OR for 2 vs 0 alleles, 1.31 [95% CI, 0.64-2.68], P = .45; OR for 1 vs 0 alleles, 0.75 [95% CI, 0.54-1.04], P = .08; and OR for 2 vs 1 allele, 1.76 [95% CI, 0.97-3.19], P = .06; overall P = .03) but not with fewer than 2 or lobar CMBs. Prevalence estimates of CMBs ranged from 6% at 50 years of age in a non-APOE ε4 allele carrier with no amyloid pathology and no cognitive impairment to 52% at 90 years of age in an APOE ε4 homozygote carrier with amyloid pathology and cognitive impairment. CONCLUSIONS AND RELEVANCE: In this cross-sectional study of 4080 participants, prevalence estimates of CMBs were associated with amyloid status, APOE ε4 copy number, and age. CMB prevalence estimates may help inform safety evaluations for antiamyloid clinical trials.

• MeSH
• Alzheimer Disease * epidemiology   genetics   MeSH
• Amyloid beta-Peptides * metabolism   cerebrospinal fluid   MeSH
• Plaque, Amyloid pathology   MeSH
• Apolipoprotein E4 genetics   MeSH
• Biomarkers * cerebrospinal fluid   MeSH
• Cerebral Hemorrhage * epidemiology   MeSH
• Middle Aged MeSH
• Humans MeSH
• Magnetic Resonance Imaging methods   MeSH
• Positron-Emission Tomography MeSH
• Cross-Sectional Studies MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH

BACKGROUND: Covert brain infarcts are associated with important neurological morbidity. Their incidence in patients with embolic stroke of undetermined source (ESUS) is unknown. AIMS: To assess the incidence of covert brain infarcts and cerebral microbleeds using MRI in a prospective substudy of the NAVIGATE ESUS randomized trial and to evaluate the effects of antithrombotic therapies. METHODS: At 87 sites in 15 countries, substudy participants were randomly assigned to receive rivaroxaban 15 mg daily or aspirin 100 mg daily and underwent brain MRI near randomization and after study termination. The primary outcome was incident brain infarct (clinical ischemic stroke or covert brain infarct). Brain infarcts and microbleeds were ascertained centrally by readers unaware of treatment. Treatment effects were estimated using logistic regression. RESULTS: Among the 718 substudy participants with interpretable, paired MRIs, the mean age was 67 years and 61% were men with a median of 52 days between the qualifying ischemic stroke and randomization and a median of seven days between randomization and baseline MRI. During the median (IQR) 11 (12) month interval between scans, clinical ischemic strokes occurred in 27 (4%) participants, while 60 (9%) of the remaining participants had an incident covert brain infarct detected by MRI. Assignment to rivaroxaban was not associated with reduction in the incidence of brain infarct (OR 0.77, 95% CI 0.49, 1.2) or of covert brain infarct among those without clinical stroke (OR 0.85, 95% CI 0.50, 1.4). New microbleeds were observed in 7% and did not differ among those assigned rivaroxaban vs. aspirin (HR 0.95, 95% CI 0.52-1.7). CONCLUSIONS: Incident covert brain infarcts occurred in twice as many ESUS patients as a clinical ischemic stroke. Treatment with rivaroxaban compared with aspirin did not significantly reduce the incidence of covert brain infarcts or increase the incidence of microbleeds, but the confidence intervals for treatment effects were wide.Registration: https://www.clinicaltrials.gov. Unique identifier: NCT02313909.

• MeSH
• Aspirin therapeutic use   MeSH
• Cerebral Hemorrhage drug therapy   MeSH
• Stroke * diagnostic imaging   drug therapy   prevention & control   MeSH
• Double-Blind Method MeSH
• Embolic Stroke * MeSH
• Factor Xa Inhibitors therapeutic use   MeSH
• Intracranial Embolism * diagnostic imaging   drug therapy   epidemiology   MeSH
• Humans MeSH
• Magnetic Resonance Imaging MeSH
• Brain Infarction diagnostic imaging   drug therapy   etiology   MeSH
• Prospective Studies MeSH
• Rivaroxaban therapeutic use   MeSH
• Aged MeSH
• Check Tag
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Randomized Controlled Trial MeSH

Importance: The reported associations of cerebral microbleeds with recurrent stroke and intracerebral hemorrhage have raised concerns regarding antithrombotic treatment in patients with a history of stroke and microbleeds on magnetic resonance imaging. Objective: To characterize microbleeds in embolic strokes of undetermined source (ESUS) and report interactions between microbleeds and the effects of random assignment to anticoagulant vs antiplatelet therapy. Design, Setting, and Participants: Subgroup analyses of the New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs Aspirin to Prevent Embolism in ESUS (NAVIGATE ESUS) international, double-blind, randomized, event-driven phase 3 clinical trial. Participants were enrolled between December 2014 and September 2017 and followed up for a median of 11 months. The study setting included 459 stroke recruitment centers in 31 countries. Patients aged 50 years or older who had neuroimaging-confirmed ESUS between 7 days and 6 months before screening were eligible. Of these 7213 NAVIGATE ESUS participants, 3699 (51%) had information on cerebral microbleeds reported on their baseline clinical magnetic resonance imaging and were eligible for these analyses. Patients with a prior history of symptomatic intracerebral hemorrhage were excluded from the NAVIGATE ESUS trial. Interventions: Rivaroxaban, 15 mg, compared with aspirin, 100 mg, daily. Main Outcomes and Measures: The primary outcome was recurrent stroke. Secondary outcomes were ischemic stroke, intracerebral hemorrhage, and all-cause mortality. Results: Microbleeds were present in 395 of 3699 participants (11%). Of patients with cerebral microbleeds, mean (SD) age was 69.5 (9.4) years, 241 were men (61%), and 201 were White (51%). Advancing age (odds ratio [OR] per year, 1.03; 95% CI, 1.01-1.04), East Asian race/ethnicity (OR, 1.57; 95% CI, 1.04-2.37), hypertension (OR, 2.20; 95% CI, 1.54-3.15), multiterritorial infarcts (OR, 1.95; 95% CI, 1.42-2.67), chronic infarcts (OR, 1.78; 95% CI, 1.42-2.23), and occult intracerebral hemorrhage (OR, 5.23; 95% CI, 2.76-9.90) were independently associated with microbleeds. The presence of microbleeds was associated with a 1.5-fold increased risk of recurrent stroke (hazard ratio [HR], 1.5; 95% CI, 1.0-2.3), a 4-fold risk of intracerebral hemorrhage (HR, 4.2; 95% CI, 1.3-13.9), a 2-fold risk of all-cause mortality (HR, 2.1; 95% CI, 1.1-4.3), and strictly lobar microbleeds with an approximately 2.5-fold risk of ischemic stroke (HR, 2.3; 95% CI, 1.3-4.3). There were no interactions between microbleeds and treatment assignments for recurrent stroke, ischemic stroke, or all-cause mortality. The HR of intracerebral hemorrhage on rivaroxaban was similar between persons with microbleeds (HR, 3.1; 95% CI, 0.3-30.0) and persons without microbleeds (HR, 3.0; 95% CI, 0.6-14.7; interaction P = .97). Conclusions and Relevance: Microbleeds mark an increased risk of recurrent stroke, ischemic stroke, intracerebral hemorrhage, and mortality in ESUS but do not appear to influence effects of rivaroxaban on clinical outcomes. Trial Registration: ClinicalTrials.gov Identifier: NCT02313909.

• MeSH
• Anticoagulants therapeutic use   MeSH
• Aspirin therapeutic use   MeSH
• Cerebral Hemorrhage epidemiology   etiology   MeSH
• Double-Blind Method MeSH
• Embolic Stroke complications   drug therapy   MeSH
• Middle Aged MeSH
• Humans MeSH
• Prevalence MeSH
• Recurrence MeSH
• Rivaroxaban therapeutic use   MeSH
• Aged MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Clinical Trial, Phase III MeSH
• Research Support, Non-U.S. Gov't MeSH
• Randomized Controlled Trial MeSH

Autoři se v článku věnují problematice protidestičkové léčby po nekardioembolické ischemické mozkové cévní příhodě. Ta s sebou nese některé kontroverzní otázky, např. zda volit monoterapii či antiagregancia kombinovat, jak dlouho léčbu podávat, či zda v případě vzniku příhody terapii měnit nebo ponechat léčbu stávající. Záměrem je diskuze i nad spornými otázkami, např. jaké je riziko takové léčby u pacientů s přítomností cerebrálních mikrokrvácení. V otázce duální terapie v úvodu léčby se odborníci shodují, nicméně pokud jde o následnou monoterapii, pohled na volbu léčiva i délku jeho podávání se mezi odborníky liší. Ke stanovení optimálního postupu chybí podklady z klinických studií.

The authors address the topic of antiplatelet therapy after a non-cardioembolic ischaemic stroke. They discuss some controversial issues in therapy such as monotherapy versus combination therapy, short-term versus long-term therapy and whether current therapy should be modified or continued in the event a patient has experienced a stroke. Other outstanding issues dealt with include e.g., the risk of such therapy in patients developing cerebral microbleeds. While consensus has been reached by experts regarding the utility of dual therapy in the initial period, divergent opinions exist as to the selection of drugs and therapy duration. Definition of the optimal strategy is hindered by the lack of evidence and robust data from clinical trials.

• Keywords
• monoterapie,
• MeSH
• Aspirin therapeutic use   MeSH
• Dipyridamole therapeutic use   MeSH
• Dual Anti-Platelet Therapy methods   MeSH
• Ischemic Stroke * drug therapy   prevention & control   MeSH
• Clopidogrel therapeutic use   MeSH
• Humans MeSH
• Secondary Prevention methods   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Review MeSH

Devětatřicetiletý muž s anamnézou plastiky bikuspidální aortální chlopně byl přijat po autonehodě do Fakultní nemocnice Ostrava pro pravostrannou hemiparézu, zpomalené psychomotorické tempo a dezorientaci. Vstupní výpočetní tomografie (CT) prokázala subarachnoidální krvácení temporo-parietálně. Magnetická rezonance (MR) mozku odhalila difuzně lokalizovaná prokrvácená ischemická ložiska. Z ostatních vážných poranění měl nemocný rupturu sleziny s následným hemoperitoneem, která si vynutila urgentní splenektomii. V klinickém obraze nemocného dominovala neurologická symptomatologie, doplněná o petechie na končetinách a průkaz Staphylococcus aureus v likvoru i v hemokulturách. Z tohoto důvodu byla stanovena pracovní diagnóza meningoencefalitidy a nemocný byl léčen kombinací antibiotik. Vstupní transtorakální i transezofageální echokardiografické vyšetření bylo negativní. Teprve kontrolní jícnová echokardiografie, provedená s odstupem dvou týdnů od první pro recidivu febrilií, detekovala vegetace na aortální, mitrální chlopni a absces prominující na síňovou stranu předního mitrálního cípu. Vzhledem k nálezu vegetací byla přehodnocena diagnóza na infekční endokarditidu se septickými embolizacemi do mozku. Pro selhání konzervativní terapie infekční endokarditidy byla provedena náhrada aortální a mitrální chlopně, následovaná protrahovanou antibiotickou léčbou dle citlivosti. Dodatečným anamnestickým šetřením bylo zjištěno, že měsíc před manifestací onemocnění pacient utrpěl řezné poranění bérce, což mohla být vstupní brána infekce. Kazuistika prezentuje případ nemocného s obtížně a opožděně diagnostikovanou infekční endokarditidou, kde razantní antibiotická i chirurgická léčba vedla k plnému vyléčení nemocného.

A 39-year-old male with a history of bicuspid aortic valvuloplasty was admitted after a car accident for right-sided hemiparesis, cognitive slowing, and disorientation to the Teaching Hospital in Ostrava. Computed tomography (CT) at admission detected subarachnoidal bleeding in the temporoparietal region. Moreover, magnetic resonance imaging (MRI) detected small diffuse ischaemic lesions surrounded by microbleeds. Amongst other major injury, the patient suffered from splenic rupture, which led to urgent splenectomy. Major symptoms were of neurological origin, accompanied by forearm petechia and confirmed presence of Staphylococcus aureus in both blood samples and cerebrospinal fluid. Therefore preliminary diagnosis of meningoencephalitis was established and the patient was treated with combination of antibiotics. Transthoracic and transesophageal echocardiography at admission was negative. Not until the second echocardiography, performed two weeks after the first one, due to elevated body temperature, vegetations on both aortic and mitral valve and the abscess on atrial side of anterior mitral valve leaflet were observed. Therefore the meaning of petechia was rethought, and a new diagnosis of infective endocarditis (IE) with septic brain emboli was established. Due to the apparent failure of conservative treatment, the patient underwent aortic and mitral valve replacement, followed by prolonged cultivation-based antibiotic therapy. In addition, one month before the presentation patient suffered from cut injury of his shank, which may have been the entrance point of infection. This case report presents an elaborate and delayed IE diagnosis where both vigorous antibiotic and surgical treatment led to full recovery of the patient.

• Keywords
• abdominalgie,
• MeSH
• Anti-Bacterial Agents therapeutic use   MeSH
• Pain etiology   MeSH
• Heart Valve Prosthesis Implantation MeSH
• Accidents, Traffic MeSH
• Adult MeSH
• Echocardiography, Transesophageal MeSH
• Endocarditis * surgery   diagnosis   etiology   pathology   MeSH
• Hemoperitoneum diagnostic imaging   MeSH
• Fever etiology   MeSH
• Intracranial Embolism MeSH
• Brain Ischemia diagnostic imaging   pathology   MeSH
• Humans MeSH
• Magnetic Resonance Imaging MeSH
• Meningoencephalitis diagnosis   MeSH
• Brain diagnostic imaging   pathology   MeSH
• Neurologic Manifestations * MeSH
• Treatment Failure MeSH
• Paresis etiology   MeSH
• Lung diagnostic imaging   pathology   MeSH
• Tomography, X-Ray Computed MeSH
• Leg Injuries complications   MeSH
• Purpura etiology   MeSH
• Splenic Rupture surgery   diagnostic imaging   MeSH
• Splenectomy MeSH
• Heart Valves surgery   pathology   MeSH
• Staphylococcal Infections etiology   blood   cerebrospinal fluid   MeSH
• Staphylococcus aureus pathogenicity   MeSH
• Subarachnoid Hemorrhage diagnostic imaging   pathology   MeSH
• Treatment Outcome MeSH
• Confusion etiology   MeSH
• Check Tag
• Adult MeSH
• Humans MeSH
• Male MeSH
• Publication type
• Case Reports MeSH

• MeSH
• Cerebral Hemorrhage * MeSH
• Humans MeSH
• Magnetic Resonance Imaging MeSH
• Nerve Fibers, Myelinated * MeSH
• Check Tag
• Humans MeSH
• Publication type
• Letter MeSH
• Comment MeSH
• Research Support, Non-U.S. Gov't MeSH

BACKGROUND: To review our experience with morphological developments during the long-term follow-up of patients treated by Gamma Knife radiosurgery for mesial temporal lobe epilepsy. METHOD: Between 1995 and 1999, we treated 14 patients with marginal doses of 24 Gy (n = 6) and 18-20 Gy (n = 8). Nine of these were operated on for insufficient seizure control. We reviewed seizure outcome and magnetic resonance images in both operated and unoperated patients and also re-examined histopathology specimens. RESULTS: Of the nine operated patients, two were Engel IIIA, one was IVA, five were IVB, and one was Engel IVC prior to surgery. At their final visit, five cases had become Engel class IA, one patient was ID, and two were IIC. In one patient the follow-up was not long enough for classification. Of the five unoperated patients, one was Engel class IB, one was IIIA, one IIB and one IVB at their final visit. Radionecrosis developed in 11 patients, occurring more often and earlier in those treated with higher doses. Collateral edema reached outside the temporal lobe in six patients, caused uncal herniation in two and intracranial hypertension in three. During longer follow-up, postnecrotic pseudocysts developed in 9 patients, and postcontrast enhancement persisted for 2.5-16 years after GKRS in all 14 patients. In five of them we detected its progression between 2 and 16 years after treatment. Signs of neoangiogenesis were found in two patients and microbleeds could be seen in five. Histopathology revealed blood vessel proliferation and macrophage infiltration. CONCLUSIONS: Early delayed complications and morphological signs suggesting a risk of development of late delayed complications are frequent after radiosurgery for mesial temporal lobe epilepsy. Together with its unproven antiseizure efficacy, these issues should be taken into account when planning future studies of this method.

• MeSH
• Child MeSH
• Adult MeSH
• Epilepsy, Temporal Lobe surgery   MeSH
• Middle Aged MeSH
• Humans MeSH
• Magnetic Resonance Imaging MeSH
• Adolescent MeSH
• Radiosurgery adverse effects   MeSH
• Temporal Lobe pathology   surgery   MeSH
• Check Tag
• Child MeSH
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Adolescent MeSH
• Male MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH

• MeSH
• Cerebral Hemorrhage diagnosis   etiology   MeSH
• Humans MeSH
• Magnetic Resonance Imaging MeSH
• Cerebral Amyloid Angiopathy complications   diagnosis   MeSH
• Aged MeSH
• Ischemic Attack, Transient diagnosis   MeSH
• Check Tag
• Humans MeSH
• Male MeSH
• Aged MeSH
• Publication type
• Letter MeSH
• Case Reports MeSH
• Research Support, Non-U.S. Gov't MeSH